Fasinumab

From WikiProjectMed
Jump to navigation Jump to search
Fasinumab
Monoclonal antibody
Type?
SourceHuman
TargetHNGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
  • 1190239-42-9
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6406H9896N1700O2026S46
Molar mass144618.27 g·mol−1

Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]

This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.

It is currently at Phase III trials.

See also

References

  1. ^ "Fasinumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
  2. ^ Tiseo PJ, Ren H, Mellis S (2014). "Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study". Journal of Pain Research. 7: 523–30. doi:10.2147/JPR.S65974. PMC 4155988. PMID 25210473.